Sana Biotechnology (SANA) Total Liabilities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Total Liabilities data on file, last reported at $254.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 7.6% year-over-year to $254.4 million; the trailing twelve-month figure through Mar 2026 stood at $254.4 million (up 7.6% YoY), and the FY2025 full-year result was $256.0 million, up 2.19% from the prior year.
• Total Liabilities declined to $254.4 million in Q1 2026, from $256.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $352.1 million in Q2 2023 to a low of $236.4 million in Q1 2025.
• A 5-year average of $286.8 million and a median of $277.8 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities retreated 22.81% in 2025 and climbed 7.6% in 2026, its largest moves.
• Tracing SANA's Total Liabilities over 5 years: stood at $323.4 million in 2022, then dropped by 14.1% to $277.8 million in 2023, then dropped by 9.82% to $250.5 million in 2024, then gained by 2.19% to $256.0 million in 2025, then decreased by 0.65% to $254.4 million in 2026.
• Business Quant data shows SANA's Total Liabilities at $254.4 million in Q1 2026, $256.0 million in Q4 2025, and $240.1 million in Q3 2025.